Drug Trial Radar · NCT07938606
MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- Shanghai Mabgeek Biotech.Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase Ib/II Study of MG-K10 in Pediatric Patients (6-12 Years) with Moderate to Severe Atopic Dermatitis Primary Objective: To evaluate the safety of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe atopic dermatitis (AD). Secondary Objectives: To evaluate the pharmacokinetic (PK) characteristics, preliminary efficacy, pharmacodynamic (PD) characteristics, and immunogenicity of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe AD.
Conditions
- Atopic Dermatitis
Interventions
Emollient (moisturizer)Other
Group A: MG-K10 humanized monoclonal antibody injection Group B: MG-K10 humanized monoclonal antibody injection Group C: MG-K10 humanized monoclonal antibody injection Group D:MG-K10 humanized monoclonal antibody injection
MG-K10 humanized monoclonal antibody injectionDrug
Subcutaneous injection; dosing regimen (loading + maintenance dose and interval) as assigned per weight-based group; treatment period 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse eventsTime frame: Up to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.